Navigation Links
Synvista Therapeutics Posts Letter to Stockholders on Web Site
Date:9/17/2008

t of 260 patients. As a result of accumulating data on the connection between CML levels and cardiovascular outcomes and the progress of our alagebrium development program, we have begun to commercialize our CML assay. To date, a licensee has sold more than 6,000 research- use-only tests. We are preparing the kit for 510(k) submission in the first half of 2009.

THERAPEUTICS

We have initiated two Phase 2 studies with alagebrium. Alagebrium is a proposed breaker of A.G.E.s for the treatment of heart failure.

The BENEFICIAL study, which began in November 2007, is a 100-patient study in chronic heart failure (CHF) being conducted at a single site in The Netherlands. This study is designed to involve nine months of treatment and is designed to measure the effect of alagebrium on exercise tolerance in patients with CHF. The study objective is to improve maximal oxygen consumption (VO2max), which is highly correlated with an improvement in myocardial function in patients with CHF. It also examines the ability of alagebrium to breakdown A.G.E.s by tracking levels of CML. As of the time of this writing, the study is more than 50% enrolled and is on track for completion in late 2009.

The BREAK study, which enrolled the first of 160 patients in May 2008, is a randomized, double-blind, placebo-controlled study at approximately 25 U.S. sites intended to assess the effect of six months of oral treatment with 400mg (200mg twice daily) of alagebrium versus placebo in patients with diastolic heart failure. Diastolic heart failure is particularly common among people with diabetes, and our intent is that at least one-half of the subjects enrolled in this study will have diabetes. The primary efficacy measure of the BREAK study is improvement of exercise tolerance as assessed by the six-minute walk test, an accepted regulatory endpoint. In addition, there will be a number of secondary and tertiary measurements including the effect on CML. This study also is
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
2. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
3. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
7. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
8. Synvista Therapeutics to be Featured on Wallst.net
9. Synvista Therapeutics to Present at the BIO InvestorForum 2007
10. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014   Wyle has been ... Lifecycle Mission Support Services (FILMSS) contract awarded by ... the terms of the contract, Wyle will provide ... Field, Calif. In particular, Wyle will provide program ... projects on the International Space Station and collaborative ...
(Date:7/30/2014)... 30, 2014 BCC Research ( http://www.bccresearch.com ... for Enzymes in Industrial Applications , the global market ... $7.1 billion by 2018, registering a five-year compound annual ... to be recorded in the detergent enzyme segment with ... Enzyme technology has influenced almost every sector of industrial ...
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. ... received the Day 180 List of Outstanding Issues (LOI) ... for Human Use (CHMP) for the NB32 Marketing Authorization ... SR) is an investigational drug candidate being evaluated for ... earlier Day 120 time point were adequately addressed by ...
(Date:7/30/2014)... 2014   Epic Sciences, Inc. ("Epic"), a ... to personalize and advance the treatment and management of ... Lucier as chairman of Epic,s board of directors. ... Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s board of ... rare cell analysis platform with special focus on the ...
Breaking Biology Technology:Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
... Md., Feb. 8, 2011 Spherix Incorporated (Nasdaq: ... in diabetes, metabolic syndrome and atherosclerosis; and providers of ... and pharmaceutical companies, today announced that its President, Dr. ... BIO CEO & Investor Conference to be held in ...
... Md., Feb. 8, 2011 United Therapeutics Corporation (Nasdaq: ... release its fourth quarter and annual 2010 financial results ... United Therapeutics will host a half-hour teleconference on ...  The teleconference is accessible by dialing 1-877-351-5881, with international ...
... 2011 -- A low cost, nanometer-sized drug to treat ... been developed by a group of scientists from the Hebrew ... U.S. and Japan. Diabetes is a rapidly growing ... population. Poor blood circulation arising from diabetes often results in ...
Cached Biology Technology:Spherix to Present at the 13th Annual BIO CEO & Investor Conference 2Spherix to Present at the 13th Annual BIO CEO & Investor Conference 3
(Date:7/30/2014)... from the University of Helsinki and the Universitat Autnoma ... mice morphological changes which have taken millions of years ... embryonic development of mice teeth, induced in the laboratory, ... to those observed in the fossil registry of rodent ... , To modify the development of their teeth, ...
(Date:7/30/2014)... dominance in female baboons suggests that the route to a ... to have lots of supportive sisters. , A female baboon,s ... by the rank of her mother - the higher the ... this reason, dominance rank in female baboons is thought to ... guaranteed a good spot in the pecking order, whereas females ...
(Date:7/30/2014)... HIV infection could be as simple as inserting a ... University of Washington bioengineers have discovered a potentially faster ... from contracting HIV. Their method spins the drug into ... moisture, releasing higher doses of the drug than possible ... , "This could offer women a potentially more effective, ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... wisdom teeth are not much more than an annoyance that ... in the September 17 Journal of Biological Chemistry ... for the creation of stem cells; thus, everyone might be ... he or she ever need some. Groundbreaking research back ...
... Mount Sinai School of Medicine have found that bisphenol A ... is detectable in the saliva after placement in children,s mouths. ... associated with changes in behavior, prostate and urinary tract development, ... the current issue of Pediatrics . Reins containing ...
... of Scots Pine trees, scientists have shown that the iconic ... the ancestors that colonised Britain after the end of the ... future populations, according to new results published in the journal ... an international team from the Centre for Ecology & Hydrology, ...
Cached Biology News:A smart use for wisdom teeth: Making stem cells 2Mount Sinai researchers analyze impact of chemical BPA in dental sealants used in children 2Scots Pine shows its continental roots 2
...
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Biology Products: